Lomitapide

Cat. No.: 0225LY-1235

Purity: ≥99%

Identity: Confirmed by NMR, and LC-MS.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: Lomitapide acts as a small molecule inhibitor of microsomal triglyceride transfer protein (MTP), preventing the assembly of very-low-density lipoproteins by blocking lipid absorption and triglyceride transfer.

Synonym: AEGR-733; BMS-201038; 182431-12-5; Juxtapid; AEGR-733; Lojuxta; AEGR 733; AEGR733; BMS 201038; BMS201038; Lomitapidum; BMS 201238; Lomitapide free base; 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-; DTXSID50171294; 182431-12-5 (free base); N-(2,2,2-trifluoroethyl)-9-[4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]piperidin-1-yl]butyl]fluorene-9-carboxamide; 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-(4-(4-(((4'-(trifluoromethyl)(1,1'-biphenyl)-2-yl)carbonyl)amino)-1-piperidinyl)butyl)-

CAS No.: 182431-12-5

Compound CID: 9853053

Formula: C₃₉H₃₇F₆N₃O₂

Formula Weight: 693.72

Specification

Targets&IC50: MTP: 8 nM

Relative Density: 1.34 g/cm³

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: Lomitapide can be used in metabolic pharmacology to investigate the regulation of cholesterol levels through the targeted inhibition of MTP.